BNBXOTCFinance ServicesFiscal year ends September 30
BNB PLUS CORP.
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.10−0.01 (-6.67%)
Close on Oct 19, 2026
- Market cap
- $878.33K
- P/E (TTM)
- –
- Dividend yield
- –
BNB PLUS CORP. revenue by segment
By business segment
| Revenue | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Therapeutic DNA Production Services | $583.40K | $638.42K | $451.81K | $160.40K | $213.07K | $467.21K | $147.44K | $215.71K | $278.76K | $323.35K | $77.54K | $72.00K | 96.4% | +173.8% |
| DNA Tagging and Security Products and Services | $21.91K | $385.69K | $113.58K | $39.03K | $91.32K | $220.55K | $722.85K | $271.92K | $194.03K | $275.26K | $476.93K | $185.44K | 3.6% | -76.0% |
| MDx Testing Services | – | – | – | – | – | $295.61K | $326.33K | $325.48K | $324.73K | $331.02K | $336.70K | $522.30K | – | – |
| Operating income | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Therapeutic DNA Production Services | -$3.84K | $24.87K | -$723.44K | -$4.65M | -$1.74M | -$1.42M | -$1.46M | -$1.05M | -$1.32M | -$1.17M | -$1.26M | -$1.17M | -99.8% |
| DNA Tagging and Security Products and Services | -$412.62K | $261.12K | -$65.08K | -$196.00K | -$113.26K | -$424.25K | -$328.44K | -$573.67K | -$693.95K | -$500.05K | -$784.30K | -$1.16M | +264.3% |
| Digital Asset Treasury | -$1.80M | -$5.37M | -$15.07M | – | – | – | – | – | – | – | – | – | – |
| MDx Testing Services | – | – | – | – | – | -$257.64K | -$262.48K | -$462.96K | -$231.16K | -$298.59K | -$496.51K | -$410.26K | – |
By product or service
| Revenue | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenues | $585.55K | $1.01M | $555.09K | $184.40K | $195.26K | $548.64K | $495.85K | $127.73K | $246.64K | $393.13K | $307.32K | $87.39K | 96.7% | +199.9% |
| Service revenues | $19.76K | $16.21K | $10.30K | $15.03K | $109.13K | $214.18K | $374.44K | $359.90K | $226.15K | $205.49K | $247.15K | $170.05K | 3.3% | -81.9% |
| Research and development services | – | – | $28.80K | $42.70K | $52.07K | $133.55K | $147.44K | $108.60K | $59.90K | $65.20K | $77.54K | $72.00K | – | – |
| Supply chain | – | – | $113.58K | $39.03K | $91.32K | $290.23K | $722.85K | $271.92K | $194.03K | $275.26K | $467.49K | $144.80K | – | – |
| Asset marking | – | – | – | – | – | $5.38K | – | – | $0 | $0 | $9.44K | $39.60K | – | – |
| Large Scale DNA Production | – | – | $423.01K | $117.70K | $161.00K | $333.66K | – | $107.11K | $218.86K | $258.15K | – | $0 | – | – |
| Clinical laboratory service revenues | – | – | – | – | – | $221.27K | $327.17K | $326.60K | $325.93K | $331.02K | $336.70K | $522.30K | – | – |
| Clinical laboratory testing services (over-time) | – | – | – | – | – | $220.55K | $324.58K | $324.58K | $311.58K | $324.58K | $324.58K | $507.11K | – | – |
| Clinical laboratory testing services (point-in-time) | – | – | – | – | – | $0 | $1.75K | $900 | $13.15K | $6.44K | $12.12K | $16.23K | – | – |
By region
From the segment and revenue-disaggregation notes of Bnb Plus's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.